Blog search results for Tag: Career

Science & Innovation

An Artificial Intelligence tool that could change the way we treat heart disease wowed the judges at this year’s Bright SCIdea competition. Now that the dust has settled, we asked Raphael Peralta, from the winning CardiaTec team, about winning the competition, the need for this technology, and tips for future participants. After winning this prestigious competition and coming away with the £5,000 first prize, the future is bright for co-founders Raphael Peralta, Thelma Zablocki and Namshik Han. So, how do they reflect on the story so far?

Bright SCIdea 2022 - Team CardiTec

Team CardiaTec (UK)

Tell us about CardiaTec
Cardiovascular disease is the world’s leading cause of death, and affects countless lives. Despite this, investment and innovation within the space has been severely stagnated, especially in comparison to fields such as oncology. The current treatment landscape remains unchanged, and treatments are most often prescribed in a standardised, one-size-fits-all approach. However, people are fundamentally different, and as shown by the Covid-19 pandemic, similar groups of people can experience a disease in a significantly different manner, and as such it is very important to understand biological processes at a patient level to produce effective therapeutic outcomes.

CardiaTec is leveraging artificial intelligence to structure and analyze large scale biological data that spans the full multiomic domain. This allows for a comprehensive understanding of disease pathophysiology to better develop novel and effective therapeutics for cardiovascular disease.

Casting your mind back to the moment you were announced the winner of Bright SCIdea 2020, what were your initial thoughts?
We thought we had a good opportunity to win it, but obviously when it was announced, it was a great feeling. Winning this competition is a further validation that what we are generating has real world value.

It was a great judging panel, with a breadth of experience across drug discovery and the pharmaceutical industry. We were up against immense global competition and the fact that we won shows that there’s a need for novel innovation in the cardiovascular space to ultimately drive the development of new therapeutics that are going to help change people's lives.

How did you think of the idea? Was there a ‘eureka’ moment?
The way the initial idea came about was through the identification that the cardiovascular space had a massive unmet need compared to other spaces such as oncology. I had worked with a cardiovascular company doing some consulting work and this is where it came to light.

In combination, multiomic techniques are becoming increasingly accessible in line with technological developments, which have made processes of next generation sequencing and proteomic profiling increasingly cheaper. These processes generate large amounts of data, which then lend themselves to applications of machine learning to derive biologically meaningful insights. These process, although becoming increasingly familiar in areas such as oncology, are highly underrepresented in cardiovascular disease, and thus there spans opportunity to develop completely unique and novel insights.

How does the technology work?
Here, CardiaTec uses data across genomics, epigenomics, transcriptomics, proteomics, and metabolomics, to generate novel biological insights with the help of AI and machine learning applications. Taking these many ‘omics’ into consideration is what defines a ‘multiomic’ approach. Biology is complex, and trends require full multiomic assessment to truly understand where dysregulation of specific processes is occurring, to then inform the best means of intervention.

CardiaTec is developing a platform, which with time will grow to become one of the most comprehensive foundations of cardiovascular disease biology. Results and outcomes are iteratively incorporated into the model, and new hypotheses are tried and tested across a range of pre-clinical settings. Collectively, CardiaTec aims to generate novel drug targets that can be used to help reduce the burden of disease in current and future patient population.

In the process of getting to the final, there were several opportunities to engage with entrepreneurs, investors, business leaders, and experts in intellectual property (IP). Can you share key takeaways from these sessions?
One of the most important things you can do is speak to people. Every business starts from an idea. As you start developing, you change and refine the business model. We take every chance to engage with people who have industry experience. It’s really important that we take the advice of these people on board; this is especially true in the field of biotechnology where you take risks across the technology side, the commercial side, and the biological side. It takes a lot of experience to mitigate those risks.

How difficult has it been taking that idea and turning it into a viable business proposition?
Thelma and I came out of the MPhil in Bioscience Enterprise at the University of Cambridge. It gave us this really strong foundation to start building. We also had the biological knowledge from our previous degrees. This framework, where we had key opinion leaders and great people in the field with whom we could bounce ideas off, was the first step. We saw that the idea was really positive and was received well by a lot of people. So, we thought: ‘we’re onto something’.

When building a biotech company, if you’re not passionate about it and don’t want to spend a lot of your time dedicated to the project, then it’s not going to take off. You need to be there to make changes, and really embrace and understand where you believe it’s going to go in line with the advice you've been given and the insights that you have generated.

We’re not only interested in understanding the intricate nature of biology. We’re also interested in how this has real life application in changing people’s lives. Every person we speak to has been affected in some way by cardiovascular disease.

I noticed that your presentation was really polished. Do you have any tips for people presenting in the final?
We’ve presented a lot of times so I think practice makes perfect. With a presentation, you need to be able to tell a story. It’s all about the storyline and building that image. You have to take care and be diligent in the process. Take time to make sure everything is structured correctly and that the story flows. Don’t be afraid to present to a lot of people who will give you advice. Take the time to make the amendments and run it through again and again, and see what the response is. So, take your time on the presentation to get your story across.

You were both very calm when the judges’ questions came. How did you prepare for these questions?
Out of this Cambridge network, the people we spoke to all asked the right questions. You see the pattern of these questions. They all want to know similar things. So, once we identified that pattern, we wrote down the questions that were important from our conversations and we practiced responses to these questions, which were by this point, fully embedded into the company’s business model; which then lends itself to an insightful, actionable response.

How are you going to use the £5,000 prize money and what’s next?
We’ll put the prize money towards refining of some of our technology. In terms of what’s next, Thelma (Zablocki), Namshik (Han), and I are dedicated to this company. We want to see it through and eventually make a drug that ends up reaching patients. This will take a long time.

To see that in the real world, where someone’s getting prescribed a drug that you discovered would be incredible.

>> For more on this year’s Bright SCIdea final, go to: https://www.soci.org/news/2022/3/bright-scidea-final-2022.